01—Abstract
Summary
Summary of the 10-Q filed July 30, 2025. Cited figures are marked; the original filing is the authoritative source.
DexCom, Inc. (DXCM) reported its second-quarter results for the period ending June 30, 2025, demonstrating continued revenue growth and improved profitability.
For the three months ended June 30, 2025, the company generated $1.16 billiona in revenue, a 15% increase year-over-year, driven by robust sales volume of its disposable sensors and a growing global customer base. Gross profit saw a 10% increase to $688.8 million, though the gross profit margin slightly decreased due to inefficiencies in supply availability, build configurations, and product mix. Operating income significantly improved by 35% to $212.6 million, reflecting strong revenue growth coupled with a decrease in selling, general, and administrative expenses, partly due to lower legal costs.
Net income for the quarter rose by 25% to $179.8 millionb, resulting in diluted earnings per share of $0.45. The company maintained a strong liquidity position, ending the quarter with $2.93 billion in cash, cash equivalents, and short-term marketable securities. Management is focused on product innovation, global expansion, and strategic partnerships, while also navigating regulatory considerations, including an FDA warning letter received in March 2025.
02—Key points
Key Highlights
- Revenue increased by 15% to $1.16 billion for the three months ended June 30, 2025, compared to the prior year, driven by higher sales volume of disposable sensors.
- Operating income surged by 35% to $212.6 million, indicating improved operational efficiency and revenue leverage.
- Net income grew by 25% to $179.8 million, with diluted EPS at $0.45, showcasing enhanced profitability.
- Gross profit margin experienced a slight decline due to supply chain inefficiencies and product mix changes, despite an overall increase in gross profit.
- Selling, general, and administrative expenses decreased by 1% due to lower legal expenses, partially offset by increased compensation costs.
- The company ended the quarter with a strong cash and marketable securities balance of $2.93 billion, providing ample liquidity.
- DexCom received an FDA warning letter in March 2025 concerning manufacturing processes and its quality management system, which it is actively addressing.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, Dexcom Inc kept $0.16.
- Revenue$1.16B100.0%
- Cost of revenue−$468.3M40.5%
- Gross profit$688.8M59.5%
- Operating costs−$476.2M41.2%
- Operating income$212.6M18.4%
- Interest, other & tax−$32.8M2.8%
- Net income$179.8M15.5%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed July 30, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $1.16B$1.00B | +15.2% |
| Cost of Revenue | $468.30M$377.60M | +24.0% |
| Gross Profit | $688.80M$626.70M | +9.9% |
| R&D Expenses | $148.20M$136.00M | +9.0% |
| SG&A Expenses | $328.00M$332.70M | −1.4% |
| Operating Expenses | $476.20M$468.70M | +1.6% |
| Operating Income | $212.60M$158.00M | +34.6% |
| Interest Expense | $3.80M$3.80M | 0.0% |
| Net Income | $179.80M$143.50M | +25.3% |
| EPS (Basic) | $0.46$0.36 | +27.8% |
| EPS (Diluted) | $0.45$0.35 | +28.6% |
| Shares Outstanding (Basic) | 392.10M399.20M | −1.8% |
| Shares Outstanding (Diluted) | 408.20M416.80M | −2.1% |
05—Questions
Frequently Asked Questions
What was the primary driver of DexCom's revenue growth in the second quarter of 2025?
The primary driver of DexCom's revenue growth was the increased sales volume of its disposable sensors, fueled by the continued expansion of its global customer base. The company added approximately 500,000 to 600,000 net customers (excluding Stelo customers) in 2024.
Why did DexCom's gross profit margin decrease slightly despite revenue growth?
The gross profit margin decreased slightly due to inefficiencies related to ensuring supply availability, suboptimal build configurations leading to lower production yields, and changes in product and channel mix. These factors outweighed the benefits of increased sales volume.
What is the significance of the FDA warning letter received in March 2025?
The FDA warning letter cited deficiencies in manufacturing processes and the quality management system at DexCom's facilities. While it does not currently restrict production, marketing, or distribution, the company must satisfy the FDA's requirements to resolve these issues. Failure to do so could lead to further regulatory actions, product recalls, or other adverse consequences.
How is DexCom managing its debt, particularly the upcoming maturity of its 2025 senior convertible notes?
DexCom has senior convertible notes maturing in November 2025 and May 2028. The company has sufficient liquidity from operations and existing cash reserves. While the 2025 notes are classified as current, they may be converted into cash and/or shares before maturity under certain conditions, potentially mitigating the need for a direct principal repayment. The company also has an undrawn credit facility available for general corporate purposes.
06—Continue